Grants and Contributions:
Title:
Cell Line Testing for Tumor Shrinkage
Agreement Number:
907704
Agreement Value:
$50,000.00
Agreement Date:
Jun 4, 2018 - Dec 31, 2018
Description:
Tieös Pharmaceuticals is a pre-clinical stage biotech company with the goal of creating novel small molecule inhibitors which target the unique metabolic characteristics of cancer cells.
With the use of advanced AI-based computational biology and 3D in-silico models, we have developed lead polypharmocological compounds which will each target multiple metabolic pathways simultaneously; creating synergies and reducing toxicity. Through a proprietary weighting of cancer specific metabolic pathways, we have now synthesized our five lead compounds and are conducting proof-of-concept in-vitro testing.
At Tieös, we have designed compounds which target onco-specific enzymes simultaneously – our goal is to starve cancer cells of their energy.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Moncton, New Brunswick, CA E1A 6N9
Reference Number:
172-2018-2019-Q1-907704
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
756525093
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days. The total amended value is 14,560 dollars.
Amendment Date
Nov 15, 2018
Recipient's Legal Name:
Tieos Pharmaceuticals Inc.
Federal Riding Name:
Moncton--Riverview--Dieppe
Federal Riding Number:
13007
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
3254
Amendments: